Intelligent Decision Support System (iCDSS) For Cancer 

 The Future of Precision Oncology:

Transforming Leukaemia Care with Multi Omics AI. SAQTEK delivers a powerful, Intelligent Clinical Decision Support System (iCDSS), specifically engineered to cut through the complexity of cancer care. The Leukaemia Dashboard is the inaugural module in our broader commitment to precision oncology. Our proprietary Machine Learning (ML) engine ingests, analyses, and normalizes complex, unstructured multi omics datasets (genomics, transcriptomics, proteomics, and metabolomics). It moves beyond traditional diagnostics to identify subtle, predictive biomarkers that are invisible to the human eye, informing truly personalized treatment pathways. We synthesize these critical findings with the latest clinical evidence, transforming raw data into actionable, evidence-based recommendations presented via an intuitive dashboard. This empowers physicians to make critical, high-precision decisions faster than ever before.

AWS Machine Learning Tools- Validated Trust

Built on the AWS Well-Architected Framework for Risk Mitigation:

Choosing SAQTEK is a long-term strategic investment, with an infrastructure designed for enterprise-grade security, compliance, and scalability.

Feature	Strategic Advantage
Compliance & Risk Mitigation	Our cloud solution is architected and maintained with features and controls that align with the stringent requirements of HIPAA, GDPR, and other key global healthcare regulations. We utilize advanced security and privacy controls to support the highest level of patient data privacy and significantly help reduce your regulatory risk.
Robust & Validated Architecture	Deployed exclusively on the Amazon Web Services (AWS) cloud platform, our core AI/ML workflows leverage purpose-built services like Amazon SageMaker. This system adheres strictly to the AWS Well-Architected Framework, ensuring world-class performance, exceptional operational reliability, and proactive security standards.
Elastic & Future-Proof Scalability	The underlying framework is inherently elastic and modality-agnostic. While our initial focus is on haematological malignancies (blood cancers) , the system is engineered to seamlessly incorporate future modules for solid tumors and broad oncology applications, safeguarding your technological investment and enabling growth.